EUVIMEDEUVIMED entdecken
Open Access

Vaccine Effectiveness Against Influenza A(H3N2)–Associated Hospitalized Illness: United States, 2022

Mark W Tenforde, Manish M Patel, Nathaniel M Lewis, Katherine Adams, Manjusha Gaglani, Jay S Steingrub, Nathan I Shapiro, Abhijit Duggal, Matthew E Prekker, Ithan D Peltan, David N Hager, Michelle N Gong und 19 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Mark W Tenforde und 30 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza A Virus, H3N2 Subtype, Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic was associated with historically low influenza circulation during the 2020–2021 season, followed by an increase in influenza circulation during the 2021–2022 US season. The 2a.2 subgroup of the influenza A(H3N2) 3C.2a1b subclade that predominated was antigenically different from the vaccine strain.

Methods

To understand the effectiveness of the 2021–2022 vaccine against hospitalized influenza illness, a multistate sentinel surveillance network enrolled adults aged ≥18 years hospitalized with acute respiratory illness and tested for influenza by a molecular assay. Using the test-negative design, vaccine effectiveness (VE) was measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2–negative controls, adjusting for confounders. A separate analysis was performed to illustrate bias introduced by including SARS-CoV-2–positive controls.

Results

A total of 2334 patients, including 295 influenza cases (47% vaccinated), 1175 influenza- and SARS-CoV-2–negative controls (53% vaccinated), and 864 influenza-negative and SARS-CoV-2–positive controls (49% vaccinated), were analyzed. Influenza VE was 26% (95% CI: −14% to 52%) among adults aged 18–64 years, −3% (−54% to 31%) among adults aged ≥65 years, and 50% (15–71%) among adults aged 18–64 years without immunocompromising conditions. Estimated VE decreased with inclusion of SARS-CoV-2–positive controls.

Conclusions

During a season where influenza A(H3N2) was antigenically different from the vaccine virus, vaccination was associated with a reduced risk of influenza hospitalization in younger immunocompetent adults. However, vaccination did not provide protection in adults ≥65 years of age. Improvements in vaccines, antivirals, and prevention strategies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H3N2 SubtypeInfluenza VaccinesInfluenza, HumanVaccine EfficacyAdolescentAdultAgedHumansHospitalizationSeasonsUnited StatesMaleFemaleYoung AdultMiddle AgedSARS-CoV-2

Stichwörter der Autor:innen

SARS-CoV-2antigenic driftinfluenzavaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA.
  • Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA.
  • Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Department of Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Departments of Emergency Medicine and Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • Centers for Disease Control and Prevention
  • Clinical and Translational Science Award
  • National Center for Advancing Translational Sciences
  • NIH

Zitieren

APA

Tenforde, M. W., Patel, M. M., Lewis, N. M., Adams, K., Gaglani, M., Steingrub, J. S., Shapiro, N. I., Duggal, A., Prekker, M. E., Peltan, I. D., Hager, D. N., Gong, M. N., Exline, M. C., Ginde, A. A., Mohr, N. M., Mallow, C., Martin, E. T., Talbot, H. K., Gibbs, K. W., …, & Influenza and Other Viruses in the Acutely Ill (IVY) Network (2023). Vaccine Effectiveness Against Influenza A(H3N2)–Associated Hospitalized Illness: United States, 2022. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac869

Vancouver

Tenforde MW, Patel MM, Lewis NM, Adams K, Gaglani M, Steingrub JS, et al. Vaccine Effectiveness Against Influenza A(H3N2)–Associated Hospitalized Illness: United States, 2022. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac869

BibTeX
@article{Tenforde2023,
  author = {Tenforde, Mark W and Patel, Manish M and Lewis, Nathaniel M and Adams, Katherine and Gaglani, Manjusha and Steingrub, Jay S and Shapiro, Nathan I and Duggal, Abhijit and Prekker, Matthew E and Peltan, Ithan D and Hager, David N and Gong, Michelle N and Exline, Matthew C and Ginde, Adit A and Mohr, Nicholas M and Mallow, Christopher and Martin, Emily T and Talbot, H Keipp and Gibbs, Kevin W and Kwon, Jennie H and Chappell, James D and Halasa, Natasha and Lauring, Adam S and Lindsell, Christopher J and Swan, Sydney A and Hart, Kimberly W and Womack, Kelsey N and Baughman, Adrienne and Grijalva, Carlos G and Self, Wesley H and Influenza and Other Viruses in the Acutely Ill (IVY) Network, Influenza and Other Viruses in the Acutely Ill (IVY) Network},
  title = {Vaccine Effectiveness Against Influenza A(H3N2)–Associated Hospitalized Illness: United States, 2022},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac869}
}
Kostenlos starten →